XML 46 R28.htm IDEA: XBRL DOCUMENT
v3.22.4

Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Summary of Significant Accounting Policies |
Schedule of disaggregation of revenue by major source | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31,
​ |  | 2022 |  | 2021 |  | 2020
Biopharma/Pharma | ​ | $ | 193,879 | ​ | $ | 180,203 | ​ | $ | 66,394
Animal Health | ​ |  | 33,465 | ​ |  | 33,353 | ​ |  | 7,846
Reproductive Medicine | ​ | ​ | 9,933 | ​ | ​ | 9,052 | ​ | ​ | 4,456
Total Revenues | ​ | $ | 237,277 | ​ | $ | 222,608 | ​ | $ | 78,696
Schedule of geographical revenues, by origin | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31,
​ |  | 2022 |  | 2021 |  | 2020
Americas | ​ | $ | 128,209 | ​ | $ | 120,270 | ​ | $ | 49,555
Europe, the Middle East and Africa (EMEA) | ​ |  | 42,155 | ​ |  | 59,334 | ​ |  | 20,316
Asia Pacific (APAC) | ​ |  | 66,913 | ​ |  | 43,004 | ​ |  | 8,825
Total revenues | ​ | $ | 237,277 | ​ | $ | 222,608 | ​ | $ | 78,696
Schedule of net loss per share | The following shows the amounts used in computing net loss per share (in thousands except per share data): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Years Ended December 31,
​ |  | 2022 |  | 2021 |  | 2020
Net loss | ​ | $ | (37,333) | ​ | $ | (275,528) | ​ | $ | (32,693)
Deemed dividend on Series C convertible preferred stock | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (39,492)
Paid-in-kind dividend on Series C convertible preferred stock | ​ |  | (8,000) | ​ |  | (8,196) | ​ |  | (2,844)
Net loss attributable to common shareholders | ​ | $ | (45,333) | ​ | $ | (283,724) | ​ | $ | (75,029)
Weighted average common shares outstanding - basic and diluted | ​ | ​ | 48,987,295 | ​ | ​ | 45,927,591 | ​ | ​ | 38,582,432
Net loss per share attributable to common stockholders – basic and diluted | ​ | $ | (0.93) | ​ | $ | (6.18) | ​ | $ | (1.94)
​
Schedule of number of shares excluded from the computation of diluted loss per share | The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Years Ended December 31,
​ |  | 2022 |  | 2021 |  | 2020
Stock options | ​ | 4,194,554 |  | 5,449,952 |  | 5,920,886
Restricted stock units | ​ | 727,984 | ​ | 373,849 | ​ | —
Series C convertible preferred stock | ​ | 5,664,532 | ​ | 5,443,505 | ​ | 6,474,135
Convertible Senior Notes | ​ | 4,022,734 |  | 4,022,734 |  | 4,810,002
​ | ​ | 14,609,804 |  | 15,290,040 |  | 17,205,023
​

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration